Please ensure Javascript is enabled for purposes of website accessibility

Here's Why bluebird bio Soared 15% in January

By Todd Campbell - Feb 6, 2018 at 5:10PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's progress toward becoming a commercial-stage gene-therapy company is sparking optimism.

What happened

Investors flocked to bluebird bio (BLUE -2.14%) last month, following two developments. Bluebird's management announced it could file three novel gene therapies for approval by the Food and Drug Administration by the end of next year, and Celgene (CELG) acquired Juno Therapeutics (JUNO) for $9 billion.

The potential to either begin generating significant revenue soon or be acquired by a larger company sent Bluebird's shares skyrocketing 15% in January, according to S&P Global Market Intelligence.

So what

At the J.P. Morgan Healthcare Conference in January, Bluebird's management unveiled plans that include advancing three drugs to the FDA over the next year: bb2121, a multiple myeloma CAR-T that it's developing with Celgene; lentiglobin, a therapy for beta thalassemia; and lenti-D, a treatment for cerebral adrenoleukodystrophy.

A monitor displaying stock price quotes and an ascending bar chart


The three drugs represent a significant commercial opportunity that could prompt a suitor such as Celgene to approach the company about a buyout.

The peak sales potential of bb2121 alone could be in the billions of dollars. Celgene is already the market-leading maker of drugs for multiple myeloma; its Revlimid, a first-line therapy, and Pomalyst, a third-line therapy, generate more than $10 billion per year in sales. In early-stage studies, 94% of patients who were given bb2121 responded. If pivotal studies pan out similarly, it could become the standard in fourth-line treatment.

Now what

Currently, Celgene and Bluebird will share profit on bb2121 sales in the United States, but given the size of the market opportunity, it wouldn't surprise me if Celgene considers making an offer to gain complete control over Bluebird.

However, even if no one comes knocking on Bluebird's door about a deal, it could still be a winning stock for investors. After all, it has one of the most advanced gene therapy pipelines in the industry, and that could justify a valuation that's north of its current $9.75 billion market cap.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

bluebird bio, Inc. Stock Quote
bluebird bio, Inc.
$3.20 (-2.14%) $0.07
Celgene Corporation Stock Quote
Celgene Corporation
Juno Therapeutics, Inc. Stock Quote
Juno Therapeutics, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.